# GH Research PLC (GHRS) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $20.28, market value $1.4 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). GH Research PLC reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 3.9×**. The shares trade at 3.9× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -3.7%** (5-yr avg -7.0%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -17.3%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -5.3%**. Earnings per share fell 5.3%.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Current ratio: 34.13** (quick 34.13). Current assets cover the next year's liabilities 34.13 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. GH Research PLC does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (9 analysts). 9 analysts cover GH Research PLC; the consensus is strong_buy, with an average price target of $42.89 (+111% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 43.2%** (YTD 61.4%, 3-mo -27.3%). The shares are up 43.2% over twelve months including dividends.
- **From 52-week high: -35.5%** (68.4% above the low). Trading 35% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 46**. An RSI of 46 is neutral.
- **Beta (1 yr): 1.52** (volatility 71%). Beta of 1.52 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=GHRS · Page: https://foliofundamentals.com/stocks/ghrs

Not investment advice.